Pricing Log in Create free account
Friday 6 November 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.

Revenue
+11.9%
EPS
−39.2%
Free cash flow
−52.1%

Quarter to September 2026, against a year earlier

547.43 4.93 +0.91%
Market cap
$137.5B
P/E
34.6×
Fwd P/E
33.2×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Vertex Pharmaceuticals Incorporated 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:04 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 4, 2026: 111 added · 79 removed · 88 modified

  1. Modified · OVERVIEW

    people with serious diseases, with a focus on specialty markets. We have seveneight approved medicines: five that treat the

277 more changes in this Item, word by word, in Powerpack.